^
Association details:
Biomarker:MYC amplification
Cancer:Esophageal Cancer
Drug:KB-0742 (CDK9 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

2639 / 8 - KB-0742 is active in preclinical MYC high models of TNBC, ovarian, and DLBCL cancers

Published date:
03/09/2022
Excerpt:
To better understand the connection between MYC and KB-0742 sensitivity, 11 different tumor types were evaluated preclinically...The 11 indications included head and neck, esophageal, gastric, liver, non-small cell lung cancer (NSCLC), pancreatic, ovarian, triple-negative breast cancer (TNBC), prostate, colon, and lymphoma. For 5 of the indications (head and neck, esophageal, gastric, liver, and colon), little activity was observed in cell lines and in vivo with weak correlations to MYC amplification.